We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-4.56%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$206M
AUM Growth
-$197M
Cap. Flow
-$141M
Cap. Flow %
-68.56%
Top 10 Hldgs %
61.73%
Holding
47
New
9
Increased
7
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
GYRE icon
Gyre Therapeutics
GYRE
+$8.48M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$8.06M
3
VSTM icon
Verastem
VSTM
+$7.78M
4
BTAI icon
BioXcel Therapeutics
BTAI
+$7.08M
5
MRSN
Mersana Therapeutics
MRSN
+$5.78M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$24.4M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$20.1M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$15.8M
4
ARWR icon
Arrowhead Research
ARWR
+$13.4M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
1
DELISTED
Avadel Pharmaceuticals
AVDL
$20.9M 10.15%
2,673,718
+1,048,718
+65% +$8.06M
AXSM icon
2
Axsome Therapeutics
AXSM
$10.9B
$18.1M 8.8%
308,500
-299,000
-49% -$24.4M
ADVM
3
DELISTED
Adverum Biotechnologies
ADVM
$16.7M 8.07%
170,450
+38,200
+29% +$4.45M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$1.93B
$12M 5.8%
399,500
-257,000
-39% -$6.81M
ARVN icon
5
Arvinas
ARVN
$520M
$11.3M 5.47%
280,120
-75,880
-21% -$3.55M
AUPH icon
6
Aurinia Pharmaceuticals
AUPH
$1.87B
$11.2M 5.42%
770,000
-287,500
-27% -$5.07M
BLU
7
DELISTED
BELLUS Health Inc.
BLU
$10.7M 5.18%
1,070,000
+260,000
+32% +$2.32M
KDMN
8
DELISTED
Kadmon Holdings, Inc.
KDMN
$9.89M 4.79%
2,360,000
-3,680,000
-61% -$15.8M
VSTM icon
9
Verastem
VSTM
$500M
$9.5M 4.6%
+310,078
New +$7.78M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.02B
$7.13M 3.45%
628,500
-289,000
-31% -$4.12M
ASND icon
11
Ascendis Pharma A/S
ASND
$16B
$7.12M 3.45%
63,200
+40,700
+181% +$5.29M
BTAI icon
12
BioXcel Therapeutics
BTAI
$26.2M
$7.04M 3.41%
+19,688
New +$7.08M
GYRE icon
13
Gyre Therapeutics
GYRE
$681M
$6.05M 2.93%
+184,613
New +$8.48M
RNAC icon
14
Cartesian Therapeutics
RNAC
$231M
$5.7M 2.76%
78,807
– –
APLS
15
DELISTED
Apellis Pharmaceuticals
APLS
$5.61M 2.72%
209,500
+22,000
+12% +$781K
LSACU
16
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$5.6M 2.71%
+560,000
New +$5.55M
MRSN
17
DELISTED
Mersana Therapeutics
MRSN
$4.82M 2.34%
+33,100
New +$5.78M
DRNA
18
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.71M 2.28%
256,500
-131,000
-34% -$2.55M
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.38M 2.12%
139,464
-58,036
-29% -$2.02M
KRTX
20
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$4.03M 1.95%
56,000
– –
RETA
21
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.39M 1.64%
23,500
-14,500
-38% -$2.8M
APLT
22
DELISTED
Applied Therapeutics
APLT
$3.33M 1.62%
102,000
-46,000
-31% -$1.86M
ARWR icon
23
Arrowhead Research
ARWR
$12.1B
$3.16M 1.53%
109,700
-332,800
-75% -$13.4M
RLMD icon
24
Relmada Therapeutics
RLMD
$556M
$3.1M 1.5%
+90,950
New +$3.67M
QURE icon
25
uniQure
QURE
$3.06B
$2.52M 1.22%
53,000
+28,000
+112% +$1.61M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Acuta Capital Partners held 47 positions worth $206M, down 49% from $404M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners withdrew a net $141M in Q1 2020, closing 15 positions and reducing 14 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $20.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 83% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Gyre Therapeutics worth $6.05M.

  • Acuta Capital Partners's largest Q1 2020 buy was Gyre Therapeutics: 184,613 shares worth $6.05M.
  • Acuta Capital Partners added most to Avadel Pharmaceuticals in Q1 2020, an estimated $8.06M increase.
  • Acuta Capital Partners's biggest Q1 2020 reduction was Axsome Therapeutics, cutting an estimated $24.4M.
  • Acuta Capital Partners fully exited Intra-Cellular Therapies Inc. in Q1 2020, selling an estimated $20.1M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $206M portfolio in Q1 2020.
  • Acuta Capital Partners opened 9 new positions and closed 15 in Q1 2020.
  • Acuta Capital Partners's portfolio value fell 49% quarter-over-quarter to $206M.

Based on Acuta Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.